Most Read Articles
3 days ago
There appears to be no association between aortic pulse wave velocity, a measure of vascular stiffness, and migraine, as reported in a recent study.
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
4 days ago
The dietary intake of gluten does not appear to be a risk factor for psoriasis, psoriatic arthritis or atopic dermatitis in women, reports a new study.
01 Dec 2019
Pneumonia is a common infection– affecting around 3,200 people inSingapore in 2016 – making it the thirdmost common cause of hospitalisation inthe country. Its common complications,especially with delayed or inappropriatetreatment, include bacteraemia andseptic shock, lung abscesses, pleuraleffusions, empyema, pleurisy, respiratoryfailure and renal failure.

Rituximab a potential treatment for bullous pemphigoid

01 Jul 2019
A woman who developed severe allergic reactions to anti-depressants nearly died from Steven Johnson Syndrome

Rituximab is a potential immunosuppressive treatment for bullous pemphigoid (BP), yielding high rates of remission, good steroid-sparing activity and an acceptable safety profile, reports a recent study.

Researchers retrospectively reviewed the charts of 20 BP patients (median age at treatment, 71.2 years; 50 percent female) who had received at least one dose of rituximab. Study outcomes included clinical status, BP disease activity index (BPDAI) score and adverse events related to treatment. All patients were given topical corticosteroids to use as needed.

The 20 participants contributed to 206 visits. Seventeen patients received one rituximab course, two received two courses and one received three courses. Patients received their first rituximab dose at an average of 231 days after their first visit, and participants were followed for a mean of 508 days after rituximab treatment.

Kaplan-Meier curves showed that the median time to remission and relapse after rituximab treatment was 196 and 508 days, respectively. Majority (75 percent; n=15) of patients showed durable remission after an average of 169 days after rituximab therapy. Of these, one did not require any adjuvant medication and three were maintained on minimal medication; eight achieved partial response.

Most (60 percent; n=9) of the patients who achieved durable remission no longer required prednisone, whereas those who were still on the medication took an average dose of 7.7 mg.

There were no deaths during the study period; 23 adverse events were reported during pre-rituximab phase and 23 during the post-rituximab phase. However, normalizing to rates per person-year, the incidence rate for adverse events dropped from 1.836 before rituximab to 0.827 after.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
There appears to be no association between aortic pulse wave velocity, a measure of vascular stiffness, and migraine, as reported in a recent study.
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
4 days ago
The dietary intake of gluten does not appear to be a risk factor for psoriasis, psoriatic arthritis or atopic dermatitis in women, reports a new study.
01 Dec 2019
Pneumonia is a common infection– affecting around 3,200 people inSingapore in 2016 – making it the thirdmost common cause of hospitalisation inthe country. Its common complications,especially with delayed or inappropriatetreatment, include bacteraemia andseptic shock, lung abscesses, pleuraleffusions, empyema, pleurisy, respiratoryfailure and renal failure.